Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
LUNIT INC
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR
2024-09-03 21:00
Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study
2024-08-06 21:00
Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program
2024-07-22 21:00
Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response
2024-05-24 22:07
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care
2024-05-22 21:00
Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite
2024-05-20 21:00
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
2024-04-08 21:00
Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification
2024-04-01 21:00
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
2024-03-26 21:00
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal
2024-03-18 21:00
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment - New Study in Breast Cancer Research
2024-03-14 21:00
Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured
2024-03-13 21:00
Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings
2024-02-28 22:03
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC
2024-02-16 22:03
Lunit INSIGHT CXR Excels in Lung Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology
2024-01-17 22:15
Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening
2024-01-16 22:04
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
2023-12-14 22:05
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
2023-12-11 22:30
Lunit to Advance Singapore's Healthcare System with AI-powered Solution for Medical Imaging
2023-11-30 22:10
AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology
2023-11-27 22:05
1
2
3
4
5
8